ENTRY       D11895                      Drug
NAME        Niraparib tosilate hydrate (JAN);
            Niraparib tosylate monohydrate;
            Zejula (TN)
PRODUCT     ZEJULA (GlaxoSmithKline LLC)
            ZEJULA (GlaxoSmithKline LLC)
FORMULA     C19H20N4O. C7H8O3S. H2O
EXACT_MASS  510.1937
MOL_WEIGHT  510.6052
CLASS       Antineoplastic
             DG02942  PARP inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01XK02
            Chemical structure group: DG03120
            Product (DG03120): D11895<JP/US>
EFFICACY    Antineoplastic, PARP inhibitor
  DISEASE   Ovarian cancer [DS:H00027]
            Fallopian tube cancer [DS:H01554]
            Primary peritoneal cancer [DS:H01665]
            Ovarian cancer (BRCA-mutated) [DS:H00027]
            Fallopian tube cancer (BRCA-mutated) [DS:H01554]
            Primary peritoneal cancer (BRCA-mutated) [DS:H01665]
TARGET      PARP1 [HSA:142] [KO:K24070]
            PARP2 [HSA:10038] [KO:K10798]
  PATHWAY   hsa04210(10038+142)  Apoptosis
            hsa04217(142)  Necroptosis
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
                 L01XK02 Niraparib
                  D11895  Niraparib tosilate hydrate (JAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Niraparib
                D11895  Niraparib tosilate hydrate (JAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11895  Niraparib tosilate hydrate (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02942  PARP inhibitor
               DG03120  Niraparib
                D11895  Niraparib tosilate hydrate
            Drug classes [BR:br08332]
             Antineoplastic
              DG02942  PARP inhibitor
               D11895  Niraparib tosilate hydrate
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Transferases (EC2)
               Pentosyltransferases
                PARP1
                 D11895  Niraparib tosilate hydrate (JAN) &lt;JP/US&gt;
                PARP2
                 D11895  Niraparib tosilate hydrate (JAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11895
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11895
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11895
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11895
            Drug groups [BR:br08330]
             Antineoplastic
              DG02942  PARP inhibitor
               DG03120  Niraparib
DBLINKS     CAS: 1613220-15-7
ATOM        36
            1   C8x C    12.1564  -16.5579
            2   C8x C    12.1564  -17.9552
            3   C8x C    13.3441  -18.6539
            4   C8y C    14.6016  -17.9552
            5   C8y C    14.6016  -16.5579
            6   C8y C    13.3441  -15.8593
            7   C8x C    15.9290  -18.3744
            8   N4y N    16.7674  -17.2566
            9   N5x N    15.9290  -16.1388
            10  C5a C    13.3441  -14.4620
            11  O5a O    12.1564  -13.7634
            12  N1a N    14.6016  -13.7634
            13  C8y C    18.0948  -17.2566
            14  C8x C    18.7935  -18.5141
            15  C8x C    20.1907  -18.5141
            16  C8y C    20.8894  -17.2566
            17  C8x C    20.1907  -16.0689
            18  C8x C    18.7935  -16.0689
            19  C1y C    22.2867  -17.2566
            20  C1x C    22.9853  -18.5141
            21  N1x N    24.3826  -18.5141
            22  C1x C    25.0812  -17.2566
            23  C1x C    24.3826  -16.0689
            24  C1x C    22.9853  -16.0689
            25  C8x C    26.7400  -16.5900
            26  C8x C    26.7400  -17.9900
            27  C8y C    27.9524  -18.6900
            28  C8x C    29.1649  -17.9900
            29  C8x C    29.1649  -16.5900
            30  C8y C    27.9524  -15.8900
            31  C1a C    27.9524  -20.0898
            32  S4a S    27.9524  -14.4902
            33  O1d O    26.5524  -14.4902
            34  O1d O    29.3524  -14.4902
            35  O1d O    27.9524  -13.0902
            36  O0  O    31.7800  -17.2200
BOND        38
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     4   7 2
            8     7   8 1
            9     8   9 1
            10    5   9 2
            11    6  10 1
            12   10  11 2
            13   10  12 1
            14    8  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   13  18 1
            21   19  16 1 #Down
            22   19  20 1
            23   20  21 1
            24   21  22 1
            25   22  23 1
            26   23  24 1
            27   19  24 1
            28   25  26 2
            29   26  27 1
            30   27  28 2
            31   28  29 1
            32   29  30 2
            33   25  30 1
            34   27  31 1
            35   30  32 1
            36   32  33 2
            37   32  34 2
            38   32  35 1
///
